BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30478189)

  • 1. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
    Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
    Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
    Kostron A; Friess M; Crameri O; Inci I; Schneiter D; Hillinger S; Stahel R; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2016 May; 49(5):1516-23. PubMed ID: 26590183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
    Gomez DR; Hong DS; Allen PK; Welsh JS; Mehran RJ; Tsao AS; Liao Z; Bilton SD; Komaki R; Rice DC
    J Thorac Oncol; 2013 Feb; 8(2):238-45. PubMed ID: 23247629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
    Takuwa T; Hashimoto M; Matsumoto S; Kondo N; Kuribayash K; Nakano T; Hasegawa S
    Int J Clin Oncol; 2017 Oct; 22(5):857-864. PubMed ID: 28439676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
    Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
    Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
    Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
    J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
    Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
    J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.
    Cho BC; Feld R; Leighl N; Opitz I; Anraku M; Tsao MS; Hwang DM; Hope A; de Perrot M
    J Thorac Oncol; 2014 Mar; 9(3):397-402. PubMed ID: 24445595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
    Hasegawa S; Okada M; Tanaka F; Yamanaka T; Soejima T; Kamikonya N; Tsujimura T; Fukuoka K; Yokoi K; Nakano T
    Int J Clin Oncol; 2016 Jun; 21(3):523-30. PubMed ID: 26577445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals.
    Bille A; Belcher E; Raubenheimer H; Landau D; Cane P; Spicer J; Lang-Lazdunski L
    Gen Thorac Cardiovasc Surg; 2012 May; 60(5):289-96. PubMed ID: 22453539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
    Thieke C; Nicolay NH; Sterzing F; Hoffmann H; Roeder F; Safi S; Debus J; Huber PE
    Radiat Oncol; 2015 Dec; 10():267. PubMed ID: 26715491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
    Ishibashi H; Kobayashi M; Takasaki C; Okubo K
    Gen Thorac Cardiovasc Surg; 2015 Jul; 63(7):395-400. PubMed ID: 25750109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical multimodality therapy for malignant pleural mesothelioma.
    Abdel-Rahman O; Elsayed Z; Mohamed H; Eltobgy M
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD012605. PubMed ID: 29309720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
    Lang-Lazdunski L; Bille A; Papa S; Marshall S; Lal R; Galeone C; Landau D; Steele J; Spicer J
    J Thorac Cardiovasc Surg; 2015 Feb; 149(2):558-65; discussion 565-6. PubMed ID: 25726878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.
    Bece A; Tin MM; Martin D; Lin R; McLean J; McCaughan B
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):355-62. PubMed ID: 25753747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.
    Sugarbaker DJ; Richards WG; Bueno R
    Ann Surg; 2014 Oct; 260(4):577-80; discussion 580-2. PubMed ID: 25203873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.